# A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

> **NCT06844214** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 32 (estimated)

## Conditions studied

- Myotonic Dystrophy

## Interventions

- **BIOLOGICAL:** SAR446268

## Key facts

- **NCT ID:** NCT06844214
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-23
- **Primary completion:** 2029-02-28
- **Final completion:** 2032-04-27
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06844214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06844214, "A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06844214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*